New PET radiotracer offers insight into multiple sclerosis

Combining PET scans with a novel radiotracer could help researchers track damage...Read more on AuntMinnie.comRelated Reading: Did PET scan confirm CTE in living NFL player? PET, EEG show treatment effectiveness in comatose patient PET links low serotonin levels to dementia SNMMI: PET helps track neuroinflammation in MS fMRI uncovers benefits of video games for MS patients
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

Conclusions: The brain health index is a new image analysis approach that may usefully capture combined visible brain damage in large-scale studies of ageing, neurovascular and neurodegenerative disease. The Study in Context: Next: Brain scans to identify children at high risk of developing multiple sclerosis (MS) before symptoms appear 25 Key Resources to Improve Brain Health and Mental Health Five reasons the future of brain enhancement is digital, pervasive and (hopefully) bright 10 neurotechnologies about to transform brain enhancement and brain health What are cognitive abilities and how to boost them? Solving ...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Cognitive Neuroscience Health & Wellness Technology atrophy brain health index Brain-health brain-injury cerebral small vessel diseases cognition computer-assisted image processing magnetic resonance imaging stroke Source Type: blogs
CONCLUSIONS: The observed correlation supports the validity of myelin measurement by using the MR imaging quantification method.
Source: American Journal of Neuroradiology - Category: Radiology Authors: Tags: ADULT BRAIN Source Type: research
Conclusions:SC GM atrophy is already detectable at an early stage of MS, in absence of detectable WM atrophy, and affects both the cervical and thoracic cord.Disclosure: Dr. Schlaeger has nothing to disclose. Dr. Papinutto has nothing to disclose. Dr. Zhu has nothing to disclose. Dr. Datta has nothing to disclose. Dr. Bevan has nothing to disclose. Dr. Caverzasi has nothing to disclose. Dr. Jordan has nothing to disclose. Dr. Lobach has nothing to disclose. Dr. Keshavan has nothing to disclose. Dr. Kirkish has nothing to disclose. Dr. Stern has nothing to disclose. Dr. Devereux has nothing to disclose. Dr. Baker has nothin...
Source: Neurology - Category: Neurology Authors: Tags: Neuroimaging in MS Source Type: research
Conclusions:The calculated required sample sizes indicate that spinal cord areas measured with PSIR images provide an efficient and well-powered outcome measure for clinical trials in MS.Disclosure: Dr. Datta has nothing to disclose. Dr. Papinutto has nothing to disclose. Dr. Bevan has nothing to disclose. Dr. Kirkish has nothing to disclose. Dr. Stern has nothing to disclose. Dr. Zhu has nothing to disclose. Dr. Crabtree-Hartman has received personal compensation for activities with Biogen as an advisory board member. Dr. Gelfand has received compensation for consulting on a scientific advisory board for Genentech. He als...
Source: Neurology - Category: Neurology Authors: Tags: MS Characterizations and Tools for Measurment Source Type: research
Objective:We studied the association of cognitive function with thalamic volume, lobar cortical thickness, cortical [11C] Pittsburgh compound-B (PiB) positron emission tomography (PET) and white matter (WM) PiB binding as a potential myelin marker in an aging MS population.Background:Advanced MRI techniques used in imaging myelin of brain parenchyma are not myelin-specific. In contrast, amyloid tracers such as PiB recently shown to target myelin; PET may be a candidate to image demyelinating diseases.Design/Methods:In the population-based Mayo Clinic Study of Aging, 24 of 4869 participants had MS, with a subset who underwe...
Source: Neurology - Category: Neurology Authors: Tags: Cognitive Impairment in Multiple Sclerosis: Clinical and MRI Correlates Source Type: research
Conclusions:Cross-sectional evidence supports an extension of the reserve hypothesis to physical disability in persons with MS, particularly for motor function.Disclosure: Dr. Sumowski has nothing to disclose. Dr. Rocca has received personal compensation for activities with Novartis, Biogen Idec, Teva Neurosciences and Genzyme as a speaker. Dr. Leavitt has nothing to disclose. Dr. Meani has nothing to disclose. Dr. Preziosa has received personal compensation for activities with Biogen Idec, Novartis and ExceMED as a speaker. Prof. Comi has received personal compensation for activities with Novartis, Teva Pharmaceutical Ind...
Source: Neurology - Category: Neurology Authors: Tags: Cognitive Impairment in Multiple Sclerosis: Clinical and MRI Correlates Source Type: research
Objective:Evaluate NeuroQuant® reliability and performance in context of an established research-based vMRI platform.Evaluate annualized Percent Brain Volume Change (PVBC) through longitudinal application of NeuroQuant® to routine MS clinical MRI scans.Background:NeuroQuant® is a volumetric (vMRI) platform used clinically in the evaluation of dementia. Although vMRI shows promise as a biomarker for MS related tissue degeneration, there remains a paucity of data regarding the application of NeuroQuant® in the monitoring of the MS disease process.Design/Methods:High-resolution T1-weighted 3D MPRAGE MRI sequen...
Source: Neurology - Category: Neurology Authors: Tags: Neuroimaging III: MRI Brain Atrophy Measurement Techniques and Analysis in Multiple Sclerosis Source Type: research
CONCLUSIONS: The authors have developed a CAD system with all its ingredients being optimized for a better detection of WMHs of all size, which shows performance close to an independent reader. PMID: 27908171 [PubMed - in process]
Source: Medical Physics - Category: Physics Authors: Tags: Med Phys Source Type: research
Royal Philips (NYSE:PHG) said today it launched its IntelliSpace Portal 9.0, the most recent iteration of its radiological visual analysis and quantification platform. The new version of the platform utilizes machine learning to aid operating radiologists in detecting, diagnosing and following-up on treatment for diseases and traumas, such as brain juries and neurological disorders including dementia, stroke, amyotrophic lateral sclerosis and multiple sclerosis. “As the rates of dementia and neurodegeneration rise, neuroradiologists need advanced tools to help referring physicians treat these challenging cases. ...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Imaging Software / IT Royal Philips Source Type: news
In conclusion, we have summarized techniques available for glycocalyx assessment, and explained the significance and technical possibilities regarding cerebrovascular glycocalyx visualization. Cerebrovascular glycocalyx assessment would add valuable information to our understanding of the pathophysiology of cerebrovascular disease. Moreover, as a part of the blood-brain barrier, more knowledge on the cerebrovascular glycocalyx may lead to better understanding of neurodegenerative conditions that are caused by a compromised blood-brain barrier including Alzheimer's disease, vascular dementia, multiple sclerosis and epilepsy...
Source: Current Neurovascular Research - Category: Neurology Authors: Tags: Curr Neurovasc Res Source Type: research
More News: Brain | Dementia | Multiple Sclerosis | Neurology | PET Scan | Radiology